AstraZeneca and China National Medicines Corporation Sign Strategic Cooperation Agreement for COVID-19 Long-Acting Antibody Drug Evusheld

According to AstraZeneca, on January 11, AstraZeneca and China Meheco Group Co., Ltd. signed a strategic cooperation framework agreement for Evusheld, AstraZeneca's long-acting neutralizing antibody combination drug for COVID-19. After the drug receives conditional approval or Emergency Use Authorization (EUA) in mainland China, both parties will sign an import and distribution agreement. During the agreement period, China Meheco will be responsible for the import and distribution of Evusheld in the mainland China market.